Health Condition 1: L639- Alopecia areata, unspecified
Conditions
Interventions
Intervention1: Tofacitinib: After baseline blood investigations and chest x-ray, tablet tofacitinib 5mg will be given once daily for 2 weeks. Blood investigations (CBC, LFT and KFT) will be repeated a
Sponsors
All India Institute of Medical Sciences, Jodhpur
Eligibility
Inclusion criteria
Inclusion criteria: 1. Clinically diagnosed patient of alopecia areata with more than 20% scalp hair loss or rapidly progressive disease. 2. Age >14 years and <50 years
Exclusion criteria
Exclusion criteria: 1. Previously treated patients within 2 weeks of topical therapy or 4 weeks of systemic therapy 2. Patients who have hepatic impairment 3. Patients with abnormal blood counts (lymphocyte cell/mm3) 4. Pregnant and lactating women. 5. Immunocompromised patients or if is a K/C/O Hepatitis B,C,or HIV 6. Patient having an active infection, any systemic illness, uncontrolled diabetes mellitus or hypertension.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in SALT Score.Timepoint: At 4 weeks, 8 weeks, 12 weeks and 16 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Physician global assessment score 2. Patient global assessment score 3. Dermatology Life Quality Index 4. Side effectsTimepoint: At 4 weeks, 8 weeks, 12 weeks and 16 weeks. | — |
Countries
India
Contacts
Public ContactDr Akhilesh Kumar Vimal
All India Institute of Medical Sciences, Jodhpur
Outcome results
None listed